Evidence map›Paper›PMID 37309820›Full record

ArticleEuropean heart journal. Cardiovascular Imaging2023

Three-dimensional echocardiographic left ventricular strain analysis in Fabry disease: correlation with heart failure severity, myocardial scar, and impact on long-term prognosis.

Josef Marek, Barbora Chocholová, Daniel Rob, Tomáš Paleček, Martin Mašek, Gabriela Dostálová, Aleš Linhart

Open access · hybridAbstract read
In one paragraph

Article in European heart journal. Cardiovascular Imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Cardiovascular imaging research and innovation in 2023.European heart journal. Imaging methods and practice · 2024
    Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Josef Marek2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 2, 128 02, Czech Republic.ORCID 0000-0002-1547-5696
Barbora Chocholová2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 2, 128 02, Czech Republic.
Daniel Rob2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 2, 128 02, Czech Republic.ORCID 0000-0002-3927-2674
Tomáš Paleček2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 2, 128 02, Czech Republic.ORCID 0000-0002-9415-5243
Martin MašekRadiology Department, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Gabriela Dostálová2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 2, 128 02, Czech Republic.ORCID 0000-0003-4809-1274
Aleš Linhart2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 2, 128 02, Czech Republic.ORCID 0000-0002-3372-7850
Charles University · CZ

Funding

Charles UniversityUniversity Hospital in Prague
6 · The paper itself

Abstract

aimsFabry disease (FD) is a multisystemic lysosomal storage disorder caused by a defect in the alpha-galactosidase A gene that manifests as a phenocopy of hypertrophic cardiomyopathy. We assessed the echocardiographic 3D left ventricular (LV) strain of patients with FD in relation to heart failure severity using natriuretic peptides, the presence of a cardiovascular magnetic resonance (CMR) late gadolinium enhancement scar, and long-term prognosis. METHODS AND

results3D echocardiography was feasible in 75/99 patients with FD [aged 47 ± 14 years, 44% males, LV ejection fraction (EF) 65 ± 6% and 51% with hypertrophy or concentric remodelling of the LV]. Long-term prognosis (death, heart failure decompensation, or cardiovascular hospitalization) was assessed over a median follow-up of 3.1 years. A stronger correlation was observed for N-terminal pro-brain natriuretic peptide levels with 3D LV global longitudinal strain (GLS, r = -0.49, P < 0.0001) than with 3D LV global circumferential strain (GCS, r = -0.38, P < 0.001) or 3D LVEF (r = -0.25, P = 0.036). Individuals with posterolateral scar on CMR had lower posterolateral 3D circumferential strain (CS; P = 0.009). 3D LV-GLS was associated with long-term prognosis [adjusted hazard ratio 0.85 (confidence interval 0.75-0.95), P = 0.004], while 3D LV-GCS and 3D LVEF were not (P = 0.284 and P = 0.324).

conclusion3D LV-GLS is associated with both heart failure severity measured by natriuretic peptide levels and long-term prognosis. Decreased posterolateral 3D CS reflects typical posterolateral scarring in FD. Where feasible, 3D-strain echocardiography can be used for a comprehensive mechanical assessment of the LV in patients with FD.

Indexed as

Echocardiography, Three-DimensionalFabry DiseaseHeart FailureVentricular Dysfunction, LeftCicatrixContrast MediaEchocardiographyFemaleGadoliniumHumansMalePrognosisReproducibility of ResultsStroke VolumeVentricular Function, LeftContrast MediaGadolinium3D echocardiographycardiovascular magnetic resonanceFabry diseaseheart failuremyocardial strain

Identifiers

PMID37309820
PMCPMC10667034
OpenAlexW4380421415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.